C Tan,
S Li, L Yi, X Zeng, L Peng, S Qin, L Wang… - Advances in …, 2021 - Springer
Introduction To estimate the cost-effectiveness of tofacitinib for patients with moderate-to-
severe rheumatoid arthritis (RA) who failed conventional synthetic disease-modifying …